TMO Stock Chart & Stats
$10644.16
-$300.00(-2.98%)
At close: 4:00 PM EDT
$10644.16
-$300.00(-2.98%)
Day’s Range― - ―
52-Week Range$7,486.00 - $11,834.00
Previous CloseN/A
Volume14.00
Average Volume (3M)97.00
Market Cap
$4.15T
Enterprise Value$228.94K
Total Cash (Recent Filing)$4.06B
Total Debt (Recent Filing)$42.55B
Price to Earnings (P/E)35.0
Beta0.03
Next Earnings
Oct 28, 2026EPS Estimate
108.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.62
Shares Outstanding369,747,280
10 Day Avg. Volume48
30 Day Avg. Volume97
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11,125.82Price Target Upside4.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)424.22
Revenue Forecast (FY)$808.87B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring Revenue ModelThermo Fisher combines recurring consumables, service contracts, diagnostics, and biopharma services with instrument sales that generate follow-on demand. This diversified model embeds the company in research, clinical, and manufacturing workflows, supporting customer retention and steadier revenue over time.
Strong Cash GenerationRobust operating and free cash flow demonstrates strong earnings conversion and provides internal funding for research, acquisitions, dividends, buybacks, and debt service. The scale and growth of cash generation improve financial resilience and support continued investment across the business.
Product Innovation And Share GainsContinued launches across mass spectrometry, chromatography, thermal cycling, and AI-enabled laboratory solutions can deepen customer adoption and reinforce Thermo Fisher’s technology position. Innovation also supports workflow integration, recurring consumables demand, and potential share gains.
Bears Say
Elevated Leverage And Interest CostHigher leverage increases the portion of cash flow committed to financing and reduces flexibility for acquisitions, investment, or shareholder returns. At 3.6x gross debt to adjusted EBITDA, elevated interest expense could constrain earnings and make the company more sensitive to operating pressure.
Margin Compression Versus Prior PeaksAlthough current profitability remains strong, lower gross and net margins than in 2021–2022 indicate that prior earnings quality and operating leverage have not fully returned. Persistent mix or cost pressure could limit profit growth even if revenue continues expanding.
Microbiology Divestiture Earnings DragThe microbiology divestiture creates a lasting reduction in the revenue base and adjusted earnings, including additional dilution in the first full year after closing. Execution around the transaction and redeployment of proceeds will therefore matter to restoring growth and per-share earnings.
Thermo Fisher News
TMO FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was $7486.00 and its highest was $11834.00 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is $4.15T.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Oct 28, 2026 which is in 37 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Jul 23, 2026. The company reported $101.98 earnings per share for the quarter, beating the consensus estimate of $96.721 by $5.26.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher does not currently pay dividends.
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 108.39.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 369,747,280 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of $101.98 in its last earnings report, beating expectations of $96.721. Following the earnings report the stock price went up 10.206%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in MX:TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11,125.82 (4.53% Upside)
$11,125.82 (4.53% Upside)
Blogger Sentiment
Bullish
MX:TMO Sentiment 67%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $182.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.88%
12-Months-Change
Fundamentals
Return on Equity
0.28%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: double-digit reported revenue growth, a clean beat to prior guidance, margin expansion, robust free cash flow, successful acquisition integration, numerous product launches and an upward revision to full-year guidance. The primary negatives were modest and manageable: the planned microbiology divestiture (small near-term revenue and EPS drag and future dilution), lingering softness in certain end markets (academic/government and parts of China), some unfavorable product mix impacts, a reduced FX tailwind and elevated leverage. Overall, the positives in the quarter — including beats, guidance raise, margin expansion and strong cash generation — substantially outweigh the lowlights.View all MX:TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
TMO Stock 12 Month Forecast
Average Price Target
$11,125.82
▲(4.53% Upside)